CJC-1295 (No DAC)
A modified GHRH(1-29) analogue engineered for improved proteolytic stability via Ala2 → D-Ala and substitutions at positions 8, 15, 27. Lacks the Drug Affinity Complex (DAC) maleimide linker, yielding a shorter-acting profile than CJC-1295 DAC. Used in pulsatile GH axis research requiring defined, time-limited stimulation.
Free COA included · Free shipment protection · 99%+ purity by HPLC & MS · Lyophilized powder
Certificate of Analysis — Included Free
Every batch independently tested by U.S.-accredited labs. Lot-matched COA confirms identity, purity ≥99% by HPLC, and safety screening.
Research Overview
CJC-1295 without DAC is a synthetic GHRH(1-29) analogue engineered with four amino acid substitutions to improve resistance to DPP-IV and serine protease cleavage relative to native GHRH. The modifications include D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27, each selected to block common proteolytic cleavage sites while preserving GHRHR binding affinity.
Unlike CJC-1295 with DAC (which contains a maleimide moiety that covalently binds serum albumin to extend half-life), the no-DAC form lacks this attachment chemistry. As a result, it has a shorter plasma half-life in animal models, providing a pharmacological tool for studying the GH axis response to intermittent GHRH stimulation without the continuous receptor engagement associated with the albumin-bound form.
In vitro and animal research has used CJC-1295 (no DAC) alongside sermorelin and the DAC form to characterize the differential effects of brief vs. sustained GHRH receptor stimulation on pituitary somatotroph desensitization, GH pulse amplitude, and IGF-1 production kinetics. It is commonly co-administered with GHRP-2 or ipamorelin in synergistic GH axis research protocols.
All referenced studies are preclinical or in vitro. Not for human use.
Molecular Information
| Full Name / IUPAC | CJC-1295 (No DAC) |
| CAS Number | 863288-34-0 |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | 3,367.9 g/mol |
| Sequence / Structure | GHRH(1-29) modified: D-Ala2, Gln8, Ala15, Leu27 substitutions; C-terminal amide |
| Appearance | White lyophilized powder |
| Solubility | Soluble in sterile water or 0.1% acetic acid |
| Format | Lyophilized (freeze-dried) powder |
| SKU | CL-034 |
Quality & Testing
- Purity: ≥99% by HPLC
- Identity: Confirmed by Mass Spectrometry (LC-MS)
- Heavy Metals: Screened; below detection thresholds
- Endotoxin: Tested per LAL assay
- Lot Tracking: Lot number on every vial matches published COA
- Packaging: Nitrogen-purged, sealed glass vials
Storage & Handling
- Short-term: Room temperature (15–25°C), dry, dark — up to 4 weeks
- Long-term: Refrigerated at 2–8°C — up to 18 months lyophilized
- Extended: −20°C; avoid freeze-thaw cycling
- Store at −20°C. Reconstituted: stable 14 days at 4°C.
This compound is supplied for in vitro research and laboratory use only. It is not for human or veterinary use, is not a drug or dietary supplement, and has not been evaluated or approved by the FDA or any regulatory agency for any therapeutic application. Purchasers must be 18 years of age or older and qualified researchers operating in compliance with all applicable local, state, and federal regulations governing research chemicals.
